Jci_page_head_homepage_01 Jci_page_head_homepage_02
Thurman M. Wheeler, John D. Lueck, Maurice S. Swanson, Robert T. Dirksen, Charles A. Thornton
Published in Volume 117, Issue 12
J Clin Invest. 2007; 117(12):3952–3957 doi:10.1172/JCI33355
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 3
Antisense morpholino represses splicing of ClC-1 exon 7a.

(A) RT-PCR showed reduction of exon 7a inclusion 3 weeks after injection of antisense (anti) morpholino (antisense 1 + antisense 2; 5 μg each) into TA muscle of HSALR mice. Pairs of injected TA muscles from each mouse are identified as 1, 2, and 3. Muscle injected with control morpholino (inv) (10 μg) was not different from untreated HSALR muscle. HSALR and WT mice have the same (FVB) inbred strain background. int, intron, ex, exon. (B) Inclusion of exon 7a remained partially suppressed 8 weeks after injection of antisense morpholino (20 μg antisense 1 vs. 20 μg invert control). (C) ClC-1 antisense morpholino did not correct the misregulated alternative splicing of titin M-line exon 5. The percentage of ClC-1 splice products that include exon 7a is shown at 3 (D) and 8 (E) weeks following morpholino injection. Mean ± SD; n = 3 per group; **P < 0.001; *P = 0.035 antisense versus invert-treated controls; t test. (F) The level of ClC-1 mRNA was increased 3 weeks after treatment with antisense moropholino. ClC-1 mRNA level is expressed in arbitrary units relative to housekeeping gene RNA polymerase II transcription factor IIB. Mean ± SD; n = 3 per group; *P = 0.06 for antisense versus invert-treated control; t test.